Diabetes Mellitus Clinical Trial
Official title:
Characteristics of Dendritic Cells Before and After Gastric Banding
A research study to find out more about a specific white blood cell called a dendritic cell.
These cells are found in a layer of fat in the body called the omentum. The omentum is a
layer of fat that covers the bowels (intestines) and protects them.
The purpose of this study is to allow us to compare dendritic cells in normal weight
individuals to the dendritic cells of people who are extremely overweight. These cells will
be collected from the omentum, the layer of fat that covers and protects the bowels
(intestines), from the mesentery, which is another layer of fat that surrounds the
intestines directly, and from the subcutaneous tissue, which is the layer of fat just under
the skin.
Obesity continues to be a major source of morbidity and mortality in the United States. The
association between obesity and type II diabetes is well known. Several studies suggest that
fat may generate a low grade inflammatory response that may be responsible for the metabolic
changes in obese patients. More specifically, a certain type of white blood cell that causes
inflammation called a dendritic cell has been found in high concentrations in omental fat.
This cell has not been extensively studied in human patients with morbid obesity, though it
may play a central role in the development of insulin resistance. Aside from weight loss,
the surgical treatment of obesity also results in a decrease in the markers of inflammation.
Many of the comorbidities of morbid obesity improve or are cured. Laparoscopic adjustable
gastric banding is safer than other gastric bypass procedures and results in similar amounts
of weight loss after 2 years postoperatively.
Much of the work regarding dendritic cells in human subjects has been in patients with
Crohn's disease. Both the cytokine profile and characteristics of the dendritic cells have
been extensively studied in Crohn's patients, but not in obese individuals. In addition to
this, these cells have not been re-evaluated after a period of weight loss.
A more detailed analysis of the inflammation of obesity and its subsequent resolution with
weight loss will contribute to the growing body of information on this subject. Further work
will lend insight into the pathogenesis of the comorbidities of obesity and may contribute
to uncovering potential treatments for these illnesses. Dendritic cells have been
extensively studied in animal models. We now know specific cell surface markers and
signaling pathways for these cells, their responses to stimulating factors, and their
ability to secrete anti-inflammatory cytokines such as IL-10. We hope to translate these
findings to humans.
It is now recognized that chronic low-grade inflammation is the critical element leading to
insulin resistance in insulin target cells. The evidence for this is substantial, including
consistent measurements of elevated inflammatory markers in plasma from insulin
resistance/diabetic humans and rodents. This concept was further established by the recent
discovery that obese adipose tissue contains large numbers of resident macrophages. In fact,
in the lean state, about 10% of all the cell types within adipose tissue consist of
macrophages, and this number can go as high as 50% in obesity. Furthermore, FACS sorting of
adipose tissue macrophages based on surface markers, has indicated that it is a
subpopulation of macrophages which accounts for this remarkable increase. This subpopulation
involves macrophages which are positive for F4/80, CD11B and CD11C and are, therefore,
dendritic-like in their phenotype. There are also reports in the literature which suggests
that visceral adipose tissue may be particularly "inflamed" compared to subcutaneous adipose
tissue and that increased macrophage infiltration and inflammatory markers are expressed in
visceral fat. More recent evidence, in which the macrophage inflammatory pathway is
specifically disabled, in knock-out mice, conclusively demonstrates that the macrophage can
be the initiating or orchestrating cell type responsible for the inflammatory response which
ultimately leads to systemic insulin resistance.
These concepts will be assessed in using the subcutaneous and visceral fat samples obtained
under this protocol. The adipose tissue samples will be collagenase digested to release all
of the adipocytes and non-adipocyte cell types within the tissue. Using differential
centrifugation and filtration, the stromal vascular fraction (SVF) will be separated from
the adipocytes. The SVF contains the macrophages, and these cells will undergo FACS analysis
based on the expression of F4/80, CD11B and CD11C to determine the absolute number of
macrophages within a given adipose tissue sample, and the proportion of classical
macrophages versus dendritic cell-like macrophages. The cells will then be sorted, and
inflammatory marker expression will be measured in the classical macrophages (F4/80
positive, CD11B positive, but CD11C negative) versus the dendritic-like cells (F480
positive, CD11B positive, and CD11C positive). This analysis will involve direct measurement
of cytokine expression by these cells (TNF, IL-1, and IL-6) as well as PCR-based
measurements of mRNA expression of inflammatory pathway components. These measurements will
be performed on the subcutaneous and visceral adipose tissue obtained at the time of the
initial surgery, as well as on the subcutaneous adipose tissue samples at follow up after
weight reduction.
;
Observational Model: Case-Only, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03743779 -
Mastering Diabetes Pilot Study
|
||
Completed |
NCT03786978 -
Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus
|
N/A | |
Completed |
NCT01804803 -
DIgital Assisted MONitoring for DiabeteS - I
|
N/A | |
Completed |
NCT05039970 -
A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04068272 -
Safety of Bosentan in Type II Diabetic Patients
|
Phase 1 | |
Completed |
NCT03243383 -
Readmission Prevention Pilot Trial in Diabetes Patients
|
N/A | |
Completed |
NCT03730480 -
User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS)
|
N/A | |
Recruiting |
NCT02690467 -
Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm.
|
N/A | |
Completed |
NCT02229383 -
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
|
Phase 3 | |
Completed |
NCT06181721 -
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT04489043 -
Exercise, Prediabetes and Diabetes After Renal Transplantation.
|
N/A | |
Withdrawn |
NCT03319784 -
Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients
|
Phase 4 | |
Completed |
NCT03542084 -
Endocrinology Auto-Triggered e-Consults
|
N/A | |
Completed |
NCT02229396 -
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
|
Phase 3 | |
Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
Completed |
NCT01892319 -
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
|
||
Completed |
NCT05031000 -
Blood Glucose Monitoring Systems: Discounter Versus Brand
|
N/A | |
Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A |